WayPath is advancing PP211 through two parallel regulatory pathways, a veterinary track targeting canine brain tumors and a human track targeting GBM. The canine track provides faster clinical validation and generates real-world safety and efficacy data that de-risks and accelerates the human IND filing.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.
